[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-335557-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-335557-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","mitochondrial-heteroplasmy-improves-risk-prediction-for-myeloid-neoplasms-research-and-analysis","Mitochondrial heteroplasmy improves risk prediction for myeloid neoplasms - Research and analysis","","Mitochondrial heteroplasmy, defined as mutations present in a subset of cellular mitochondrial DNA, is examined as an additional marker for clonal expansion in myeloid neoplasms alongside clonal hematopoiesis of indeterminate potential (CHIP). The study analyzes how these markers co-occur and how they influence disease incidence and risk stratification. Heteroplasmy is more prevalent among individuals with CHIP, especially with higher variant allele fractions, multiple mutations, spliceosome machinery mutations, and variants predicted to be more deleterious. Adding heteroplasmy to an existing CHIP risk score improves sensitivity and better highlights high-risk groups.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/mitochondrial-heteroplasmy-improves-risk-prediction-for-myeloid-neoplasms-research-and-analysis/335557/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/mitochondrial-heteroplasmy-improves-risk-prediction-for-myeloid-neoplasms-research-and-analysis/335557.png","ImageObject",300,407,{"name":42,"@type":43},"Seraphina","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",11,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What are the two key biological markers studied for myeloid neoplasms risk?","Question",{"text":63,"@type":64},"The study focuses on clonal hematopoiesis of indeterminate potential (CHIP) and mitochondrial heteroplasmy, which refers to mutations in a subset of cellular mitochondrial DNA.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How does mitochondrial heteroplasmy relate to CHIP?",{"text":68,"@type":64},"Heteroplasmy is more common in individuals with CHIP, particularly when variant allele fractions are higher, multiple mutations are present, or spliceosome machinery mutations occur.",{"name":70,"@type":61,"acceptedAnswer":71},"Does adding heteroplasmy to existing CHIP risk scores improve prediction?",{"text":72,"@type":64},"Yes. Incorporating heteroplasmy into an existing CHIP risk score model significantly improves sensitivity and better identifies high-risk groups.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},335557,1790167340,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":4},962075114101,"https://ap-avatar.wpscdn.com/avatar/e000253a75eb197efd?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780044092746381165","Article [https://doi.org/10.1038/s41467-024-54443-3](https://doi.org/10.1038/s41467-024-54443-3)  \nMitochondrial heteroplasmy improves risk prediction for myeloid neoplasms  \nReceived: 8 May 2024  \n\n| Accepted: 7 November 2024 |\n| --- |\n| |\n| Check for updates |\n\nYun Soo Hong1,10, Sergiu Pasca2,3,10, Wen Shi 1, Daniela Puiu4, Nicole J. Lake  Monkol Lek 5, Meng Ru6, Megan L. Grove 7, Anna Prizment8,  \nCorinne E. Joshu3,6, Elizabeth A. Platz 3,6, Eliseo Guallar9, Dan E. Arking 1  Lukasz P. Gondek 2,3   \n5  \n,  \n&  \nClonal hematopoiesis of indeterminate potential is the primary pathogenic risk factor for myeloid neoplasms, while heteroplasmy (mutations in a subset of cellular mitochondrial DNA) is another marker of clonal expansion associated with hematological malignancies. We explore how these two markers relate and inﬂuence myeloid neoplasms incidence, and their role in risk stratiﬁcation. We ﬁnd that heteroplasmy is more common in individuals with clonal hematopoiesis of indeterminate potential, particularly those with higher variant allele fractions, multiple mutations, or spliceosome machinery mutations. Individuals with both markers have a higher risk of myeloid neoplasms than those with either alone. Furthermore, heteroplasmic variants with higher predicted deleteriousness increase the risk of myeloid neoplasms. Incorporating heteroplasmyin an existing risk score model for individuals with clonal hematopoiesis of indeterminate potential signiﬁcantly improves sensitivity and better identiﬁes high-risk groups. This suggests heteroplasmy as aclonal expansion marker and potentially asa biomarker for myeloid neoplasms development.  \nScreening, detection, and control of early malignancy or premalignant lesions are the hallmark of secondary prevention of cancer. This set of interventions, while successfully applied in various solid tumor malignancies, has not been widely adopted in myeloid neoplasms (MN), likely due to the lack of precise biomarkers of MN risk1–3. In recent years, signiﬁcant progress has been made, fueled mainly by advances in cancer genomics and next-generation sequencing (NGS). The broad application of this technology to large population-based cohorts, providing easy access to sequencing data for the scientiﬁc community, allowed for the identiﬁcation of clonal expansion of  \nhematopoietic cells, also known as clonal hematopoiesis (CH), in over 10% of the adult population4–7. The most studied form of CH is clonal hematopoiesis of indeterminate potential (CHIP), which is deﬁned asthe presence of cancer-associated somatic mutations in hematopoietic cells in otherwise healthy individuals. Given its clonal nature, it is not surprising that some forms of CHIP are myeloid premalignant conditions. Most recently, multiparameter MN prediction models including somatic mutations, hematologic indices, and demographic data have been developed to identify the population with CHIP at high risk for developing MN8,9. Unfortunately, these risk scoring systems are limited  \n1McKusick-Nathans Institute, Department of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 2Division of Hematological Malignancies, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 3Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD, USA. 4Department of Biomedical Engineering, Johns Hopkins University, Baltimore, MD, USA. 5Department of Genetics, Yale School of Medicine, New Haven, CT, USA. 6Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA. 7Human Genetics Center; Department of Epidemiology, Human Genetics, and Environmental Sciences; School of Public Health, The University of Texas Health Science Center at Houston, Houston, TX, USA. 8Department of Laboratory Medicine & Pathology, University of Minnesota Medical School, Minneapolis, Minnesota, USA. 9Department of Epidemiology, School of Global Public Health, New Y","cbCainl9y4IC8abi","https://ap.wps.com/l/cbCainl9y4IC8abi","pdf",1103313,15,"English","# Background\n## Cancer screening and the need for biomarkers\n## Clonal hematopoiesis and risk models\n## Mitochondrial heteroplasmy as a lineage marker\n# Study design and cohorts\n## UK Biobank\n## ARIC study\n# Key findings\n## Heteroplasmy prevalence in CHIP\n## Combined markers and elevated risk\n## Predicted deleteriousness and risk\n# Risk modeling impact\n## Improving sensitivity with heteroplasmy\n## Identifying high-risk groups","[{\"question\":\"What are the two key biological markers studied for myeloid neoplasms risk?\",\"answer\":\"The study focuses on clonal hematopoiesis of indeterminate potential (CHIP) and mitochondrial heteroplasmy, which refers to mutations in a subset of cellular mitochondrial DNA.\"},{\"question\":\"How does mitochondrial heteroplasmy relate to CHIP?\",\"answer\":\"Heteroplasmy is more common in individuals with CHIP, particularly when variant allele fractions are higher, multiple mutations are present, or spliceosome machinery mutations occur.\"},{\"question\":\"Does adding heteroplasmy to existing CHIP risk scores improve prediction?\",\"answer\":\"Yes. Incorporating heteroplasmy into an existing CHIP risk score model significantly improves sensitivity and better identifies high-risk groups.\"}]","Mitochondrial heteroplasmy improves risk prediction for myeloid neoplasms - Research and analysis | PDF",1790011430,38]